US8399010B2 - Highly-mineralized osteogenic sponge compositions and uses thereof - Google Patents
Highly-mineralized osteogenic sponge compositions and uses thereof Download PDFInfo
- Publication number
- US8399010B2 US8399010B2 US13/369,929 US201213369929A US8399010B2 US 8399010 B2 US8399010 B2 US 8399010B2 US 201213369929 A US201213369929 A US 201213369929A US 8399010 B2 US8399010 B2 US 8399010B2
- Authority
- US
- United States
- Prior art keywords
- bone
- sponge
- osteogenic
- particulate mineral
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 230000002188 osteogenic effect Effects 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 45
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 44
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 37
- 239000011707 mineral Substances 0.000 claims abstract description 37
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 18
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 18
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 18
- 230000002138 osteoinductive effect Effects 0.000 claims abstract description 7
- 102000008186 Collagen Human genes 0.000 claims description 37
- 108010035532 Collagen Proteins 0.000 claims description 37
- 229920001436 collagen Polymers 0.000 claims description 37
- 239000011159 matrix material Substances 0.000 claims description 29
- 241000288906 Primates Species 0.000 claims description 19
- 230000004927 fusion Effects 0.000 claims description 19
- 230000008468 bone growth Effects 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 14
- 239000001506 calcium phosphate Substances 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 11
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 claims description 9
- 101710121660 PDZ and LIM domain protein 7 Proteins 0.000 claims description 9
- 230000002051 biphasic effect Effects 0.000 claims description 8
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 8
- 235000011010 calcium phosphates Nutrition 0.000 claims description 8
- 210000002997 osteoclast Anatomy 0.000 claims description 7
- 210000000963 osteoblast Anatomy 0.000 claims description 6
- 230000001054 cortical effect Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 3
- 239000004068 calcium phosphate ceramic Substances 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 239000007943 implant Substances 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 description 14
- 239000002002 slurry Substances 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000011164 ossification Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000000515 collagen sponge Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 3
- 102100026632 Mimecan Human genes 0.000 description 3
- 101800002327 Osteoinductive factor Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003462 bioceramic Substances 0.000 description 3
- 230000010256 bone deposition Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000037873 arthrodesis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000045896 human BMP2 Human genes 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 241000112853 Arthrodes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241001447056 Uristes Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000046148 human BMP4 Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940052907 telazol Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates generally to osteogenic compositions. Specifically, the present invention relates to an osteogenic sponge composition effective for the induction of new bone growth in animals.
- Bone grafting has been commonly used to augment healing in the treatment of a broad range of musculoskeletal disorders. This procedure has several disadvantages. If the bone material is obtained from donors of the same species, such as an allograft, an increased risk of disease transmission and immune reaction exists. Bone material surgically removed from the patient, known as an autograft, is also undesirable because a sufficient amount of autogenous bone may not be available and the additional surgery necessary to obtain the autograft increases the risk of infection.
- Candidate compositions include collagen and a bioceramic, such as hydroxyapatite, as these components are the chief structural materials in bone tissue. Bioceramics provide a porous matrix which encourages some new bone growth but, when used in powdered form, give rise to foreign body-giant cell reactions. Other compositions include demineralized bone powder and collagen. The osteogenic potential of these compositions have been found to be less than satisfactory.
- the invention provides in one preferred embodiment an osteogenic sponge composition useful for the induction of new bone growth in a mammal.
- This composition includes a resorbable sponge matrix material and an osteogenic factor, preferably one that preferably stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in the sponge matrix material.
- the resorbable sponge matrix material is desirably a three-dimensionally stable yet flexible material, facilitating its use as an implant.
- the osteogenic factor is usually incorporated in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal.
- the composition also includes a particulate mineral having an average particle diameter of at least about 0.5 mm embedded in the resorbable sponge matrix material, wherein the particulate mineral present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. More preferred compositions are even more highly mineralized, for example wherein the particulate mineral is present in a weight ratio of at least about 10:1 relative to the resorbable sponge matrix material.
- the particulate mineral is desirably formed of a synthetic calcium phosphate ceramic or of bone, especially cortical bone.
- the osteogenic factor is most preferably BMP-2 or LMP, or comprises a nucleotide sequence encoding BMP-2 or LMP.
- Another embodiment of the present invention provides a method for inducing bone growth in a primate.
- the method includes a first step of providing an osteogenic sponge composition having a resorbable sponge matrix material and an osteogenic factor that stimulates osteoblasts and osteoclasts incorporated in the sponge matrix material in an amount that causes an increased rate of resorption of the sponge matrix material in the primate.
- Particulate mineral having an average particle diameter of at least about 0.5 mm is embedded in said resorbable sponge matrix material and present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor.
- This osteogenic sponge composition is implanted in the primate in a void in which bone growth is desired, with the osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through the void.
- Particularly preferred methods involve bone ingrowth to attain spinal fusions in humans.
- Another preferred embodiment of the invention provides an osteogenic sponge composition effective for the induction of new bone growth in a mammal (especially a primate) that includes
- a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in the resorbable sponge matrix, wherein the particulate mineral is present in an amount constituting at least about 95% by weight of the carrier.
- An osteogenic factor that stimulates osteoblasts and osteoclasts is incorporated in said carrier.
- a still further aspect of the invention provides a highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix.
- the device is comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral.
- an osteogenic factor can be incorporated in such an implant.
- a further embodiment of the invention provides an interbody spinal fusion device that includes a load bearing member sized for insertion between adjacent vertebrae and any one of the aforementioned compositions retained by the load bearing member.
- Such fusion devices can be used in inventive interbody spinal fusion methods mammals, wherein the devices are appropriately implanted to facilitate spinal fusion.
- a particular feature of the present invention relates to the discovery that the inclusion of an osteogenic factor, especially an osteoblast- and osteoclast-stimulating osteogenic factor, in a resorbable sponge composition causes a substantially accelerated resorption of the sponge. This rapid resorption can diminish or eliminate the capacity of the sponge composition to effectively stimulate and support new bone formation in a void filled with the sponge composition. This is particularly the case in primates, including humans, in which the rate of new bone formation is relatively slow.
- Objects of the present invention are to provide osteogenic sponge compositions effective for the induction of bone growth in mammals, particularly primates, including humans, and related methods and devices.
- FIGS. 1 and 2 depict a digitized images of computerized tomography (CT) scans of an L4-L5 posterolateral spinal fusions performed on rhesus monkeys as described in Example 5 (top panels, section through superior transverse processes; middle panels, section through disc space; lower panels, section through inferior transverse processes).
- CT computerized tomography
- the invention relates in certain aspects to osteogenic sponge compositions effective for the induction of new bone growth in mammals and methods for inducing bone growth in mammals.
- the present invention features osteogenic sponge compositions effective for use in primates, wherein the compositions exhibit high osteoinductive potential and provide a lasting mineral scaffold to support bone ingrowth.
- Such preferred compositions include a porous, resorbable sponge carrier, such as collagen in sponge form, and an osteogenic factor that stimulates the action of both osteoblasts (which biologically facilitate the formation of bone) and osteoclasts (which biologically facilitate the resorption of bone).
- an effective inductive amount of an osteogenic factor such as a bone morphogenetic protein (BMP)
- BMP bone morphogenetic protein
- non-mineralized sponge compositions may be highly effective for repair of bone defects in lower animals, such as mice, that have a faster bone growth rate, they are less effective in large animals such as primates, including humans.
- a feature of the present invention is the provision of an osteogenic composition in the form of a sponge that includes a substantial amount of a relatively slowly-resorbed mineral component that remains at the implant site after the carrier has been rapidly resorbed, in order to provide a scaffold for new bone formation that is not prematurely resorbed due to the osteoclastic potentiation by the bone morphogenic protein in the composition.
- the present invention also provides methods for using such osteogenic compositions in treatment of bone trauma, disease and defects, for artificial arthrodeses and for other treatment where new bone formation is desired, especially in primates, including humans.
- the sponge matrix material is preferably collagenous.
- collagen materials are suitable for the sponge matrix.
- Naturally occurring collagens may be subclassified into several different types depending on their amino acid sequence, carbohydrate content and presence or absence of disulfide cross-links.
- Types I and III collagen are two of the most common subtypes of collagen. Type I collagen is present in skin, tendon and bone whereas Type III collagen is found primarily in skin.
- the collagen in the composition may be obtained from skin, bone, tendon, or cartilage and purified by methods known in the art. Alternatively, the collagen may be purchased commercially.
- the collagen in the composition is preferably Type I bovine collagen.
- the collagen carrier can further be atelopeptide collagen and/or telopeptide collagen.
- telopeptide collagen can be used.
- non-fibrillar collagen is collagen that has been solubilized and has not been reconstituted into its native fibrillar form.
- the sponge carrier may also be formed of other natural or synthetic polymeric materials, in addition to or as an alternative to collagen.
- the sponge carrier may be formed of gelatin (e.g. foamed gelatin), in addition collagen or as an alternative to collagen.
- gelatin e.g. foamed gelatin
- Other natural and synthetic polymers are also known for the formation of biocompatible sponge materials, and can be used herein.
- compositions of the invention also include an osteoinductive factor, such as an osteoinductive protein or a nucleotide sequence encoding an osteoinductive protein operably associated with a promoter (e.g. provided in a vector such as a viral vector) which drives expression of the gene in the animal recipient to produce an effective amount of the protein.
- the osteogenic factor utilized in the present invention can be one that stimulates production or activity of osteoblasts and osteoclasts.
- the factor is preferably a bone morphogenetic protein (BMP) or a LIM mineralization protein (LMP), or comprises a nucleotide sequence encoding a BMP or LMP.
- Recombinant human BMPs are preferred, and may be commercially obtained or prepared as described and known in the art, e.g. in U.S. Pat. Nos. 5,187,076 to Wozney et al.; 5,366,875 to Wozney et al.; 4,877,864 to Wang et al.; 5,108,932 to Wang et al.; 5,116,738 to Wang et al.; 5,013,649 to Wang et al.; 5,106,748 to Wozney et al; and PCT Patent Nos. WO93/00432 to Wozney et al.; WO94/2693 to Celeste et al.; and WO94/26892 to Celeste et al.
- the osteoinductive factor may be isolated from bone. Methods for isolating BMP from bone are described in U.S. Pat. No. 4,294,753 to Urist and Urist et al., PNAS 371, 1984. Recombinant human BMP-2 (rhBMP-2), recombinant human BMP-4 (rhBMP-4), recombinant human BMP-7 (rhBMP-7) or heterodimers thereof are most preferred.
- the osteoinductive factor may also be LIM mineralization protein (LMP) or a suitable vector incorporating a gene encoding the same operably associated with a promoter, as described in WO99/06563 (see also genbank accession No. AF095585).
- such vectors are preferably delivered in conjunction with cells, for example autologous cells from the recipient of the implant.
- the vector is delivered in conjunction with autologous white blood cells derived from bone marrow or peripheral blood of the recipient. These cells may be applied to the sponge composition along with the osteogenic factor prior to implantation.
- the particulate mineral component includes a natural or synthetic mineral that is effective in providing a scaffold for bone ingrowth as the resorbable carrier is resorbed.
- the mineral may be, for example, bone, especially cortical bone, or a synthetic bioceramic such as a biocompatible calcium phosphate ceramic.
- Illustrative ceramics include tricalcium phosphate, hydroxyapatite, and biphasic calcium phosphate. These mineral components may be purchased commercially or obtained or synthesized by methods known in the art.
- Biphasic calcium phosphate is a particularly preferred synthetic ceramic for use in the invention.
- such biphasic calcium phosphate with have a tricalcium phosphate:hydroxyapatite weight ratio of about 50:50 to about 95:5, more preferably about 70:30 to about 95:5, even more preferably about 80:20 to about 90:10, and most preferably about 85:15.
- the amount of mineral in the osteogenic sponge composition must be sufficient to provide a scaffold that will remain in the patient for a period of time sufficient for the formation of osteoid in the void for which bone growth is desired. Typically, this period of time will be about 6 to about 8 weeks.
- the minimum level of mineral that must be present in the composition is also dependent on the activity of the BMP in the composition; the higher the activity of the BMP, the greater the content of the mineral matrix required to counter the osteoclastic potentiation of the BMP.
- the rate of resorption of the resorbable carrier also increases as the BMP concentration increases.
- the particulate mineral:resorbable sponge matrix weight ratio will be at least about 4:1, more preferably at least about 10:1.
- the particulate mineral will constitute at least 95% by weight of the sponge implant.
- highly effective sponge carrier devices are provided wherein they comprise about 97% to about 99% by weight particulate mineral and about 1% to about 3% of the collagen or other sponge-forming matrix material.
- the mineral component have an average particle size of at least about 0.5 mm, more preferably about 0.5 mm to about 5 mm, and most preferably about 1 mm to about 3 mm.
- a collagen slurry may be formed as known and preferably is chilled to increase its viscosity to help suspend the porous particulate mineral component.
- the porous particulate mineral is dispersed into the collagen slurry and gently mixed. After the porous particulate mineral component is uniformly dispersed in the slurry, the slurry is poured into sterile trays or other forms and freeze dried. The sheets of composite sponge are then removed from the freeze drier and exposed to a gluteraldehyde cross-linking agent.
- the composite sponge formed is generally three-dimensionally stable and can be sterilized and packaged in accordance with known procedures.
- the dimensions of the sponge produced may vary depending on the application. Dimensions of a typical sponge are, for example, about 10 cm (length) ⁇ 7.5 cm (width) ⁇ 0.35 cm (height).
- BMP or other osteogenic factors may be included in the formed sponge by combining the BMP with a liquid carrier as known in the art and infusing the liquid into the sponge.
- osteogenic enhancing factors include host compatible osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor- ⁇ , fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin- ⁇ , antibiotics and steroids.
- methods for inducing bone growth in mammals include providing the above-described osteogenic sponge composition and implanting the composition at a site at which bone growth is desired, e.g., to treat a disease, defect or location of trauma, and/or to promote artificial arthrodesis.
- the hydrated sponge composition may be rolled up prior to packing the sponge into the implantation site.
- the osteogenic sponge composition will effectively induce and support ingrowth of bone into the desired area even in a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits.
- a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits.
- the collagen carrier is resorbed relatively quickly, the substantial mineral component remains as a scaffolding to support new bone growth in and through the desired area.
- the above osteogenic sponge compositions of the present invention are especially advantageous when used in bones or bone portions that exhibit only low to moderate vascularization.
- Such low to moderate vascularized regions exhibit low rates of bone formation so rapid resorption of a carrier poses a problem.
- Examples of low to moderate vascularized sites include, for example, transverse processes or other posterior elements of the spine.
- An especially preferred use of the sponge compositions of the present invention is as an implant to promote arthrodesis between vertebrae in spinal fusions in humans or other primates, including interbody, posterior and/or posterolateral fusion techniques.
- the rate of bone formation in the primate spine is relatively slow overall and thus will benefit generally from the present invention, the elements to be fused in posterior and posterolateral fusions exhibit particularly low levels of vascularization and thus fusions of these elements are expected to benefit markedly from the invention.
- the osteogenic sponge compositions can be incorporated with a load-bearing member used in a spinal fusion, including hollow spinal cages, dowels or other devices known in the art having a pocket, chamber or other mechanism for retaining the osteogenic sponge composition.
- the load-bearing member desirably will have a compressive strength of at least about 10,000 N. Suitable such load bearing members are described, for example in U.S. Pat. Nos. 5,522,899, 5,785,710, 5,776,199 and 5,814,084, each of which is hereby incorporated by reference in its entirety.
- the present study was performed to determine the effect of the osteogenic sponge compositions of the present invention on spinal fusion.
- the experimental group included two adult rhesus monkeys ( Macaca mulatta ).
- the monkeys were anesthetized with 3-5 mg/kg telazol intramuscularly (i.m.).
- the anesthesia was maintained with 1.5-2.0% isoflurane.
- animals were shaved, prepared with betadine and sterily draped.
- the surgical site was infiltrated with 10-15 ml of 0.25% marcaine to aid with immediate postoperative analgesia.
- a midlineposterior skin incision was made over the lumbar spine.
- the paraspinal muscles were reflected using elevators, exposing the lamina and the transverse processes of the L4 and L5 vertebral bodies.
- the transverse processes of the two vertebrae to be fused were decorticated with an electric burr.
- Composite sponges having dimension of 3.5 cm ⁇ 1.4 cm ⁇ 0.35 cm, were prepared using techniques as described in Examples 1 and 2.
- the sponges included, on a weight basis, 97% biphasic calcium phosphate (15% hydroxyapatite and 85% tricalcium phosphate, 1 mm particle size) and 3% collagen.
- Recombinant human BMP-2 (rhBMP-2) was prepared at a concentration of 3.0 mg/ml in a buffered solution. Each sponge was infused with 1.5 ml of the rhBMP-2 solution.
- the sponges were placed in the paraspinal bed directly on top of and bridging the two adjacent transverse processes.
- the sponges were placed bilaterally, with two sponges (one on top of the other) on each side of the spine, resulting in a total dose of 9 mg rhBMP-2 per implant site.
- the animals were allowed to recover and move around ad libitum without restrictions during the study period.
- the spines were manually assessed for fusion upon sacrifice (2, 4 and 6 months) and determined to be fused based upon the absence of motion during attempted bending, and presence of histological bridging bone.
- FIGS. 1 and 2 show the CT scans for each subject studied.
- FIGS. 1 and 2 demonstrate the sequence of events that occur within the composite sponge carrier loaded with rhBMP-2.
- On the far left of the figures are three CT sections equally spaced throughout the fusion mass at 2 months post-operative, showing that resorption of the composite sponge is just about complete due to the lack of radiopacity of the ceramic granules.
- the three middle CT sections show these same three CT sections at four months with increased bone deposition where the carrier once resided.
- the composite sponge has maintained the space within the soft tissue site for a sufficient enough period of time for the desired volume of new bone deposition to occur.
- the far right three CT scans show even further bone deposition, remodeling and maturation with the formation of outer cortices around the periphery of the fusion masses by six months.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Prostheses (AREA)
Abstract
Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described.
Description
This application is a continuation of U.S. application Ser. No. 12/355,569, now U.S. Pat. No. 8,147,862, filed Jan. 16, 2009, the entirety of which is incorporated by reference, which is a continuation of U.S. patent application Ser. No. 09/923,116, filed Aug. 6, 2001, now U.S. Pat. No. 7,563,455, which is a continuation of 35 U.S.C. §371 of International Application No. PCT/US00/03043, filed on Feb. 4, 2000, which claims priority from U.S. Patent Application No. 60/118,615 filed on Feb. 4, 1999, which are incorporated by reference.
The present invention relates generally to osteogenic compositions. Specifically, the present invention relates to an osteogenic sponge composition effective for the induction of new bone growth in animals.
Bone grafting has been commonly used to augment healing in the treatment of a broad range of musculoskeletal disorders. This procedure has several disadvantages. If the bone material is obtained from donors of the same species, such as an allograft, an increased risk of disease transmission and immune reaction exists. Bone material surgically removed from the patient, known as an autograft, is also undesirable because a sufficient amount of autogenous bone may not be available and the additional surgery necessary to obtain the autograft increases the risk of infection.
Due to the need for safer bone graft materials, efforts have been directed to finding bone graft substitutes. Candidate compositions include collagen and a bioceramic, such as hydroxyapatite, as these components are the chief structural materials in bone tissue. Bioceramics provide a porous matrix which encourages some new bone growth but, when used in powdered form, give rise to foreign body-giant cell reactions. Other compositions include demineralized bone powder and collagen. The osteogenic potential of these compositions have been found to be less than satisfactory.
The discovery of osteogenic factors and their application to bone graft substitute compositions has increased the effectiveness of the above-mentioned compositions. Although many preparations purport to be effective in bone repair in vertebrates, including higher animals such as primates, most of the experimentation done with the compositions have involved lower animals, such as mice and rats.
In light of this background, there remains a need for improved osteogenic compositions and methods that effectively induce bone growth in higher animals, including primates.
The invention provides in one preferred embodiment an osteogenic sponge composition useful for the induction of new bone growth in a mammal. This composition includes a resorbable sponge matrix material and an osteogenic factor, preferably one that preferably stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in the sponge matrix material. The resorbable sponge matrix material is desirably a three-dimensionally stable yet flexible material, facilitating its use as an implant. The osteogenic factor is usually incorporated in an amount that causes an increased rate of resorption of said sponge matrix material in a mammal. The composition also includes a particulate mineral having an average particle diameter of at least about 0.5 mm embedded in the resorbable sponge matrix material, wherein the particulate mineral present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. More preferred compositions are even more highly mineralized, for example wherein the particulate mineral is present in a weight ratio of at least about 10:1 relative to the resorbable sponge matrix material. The particulate mineral is desirably formed of a synthetic calcium phosphate ceramic or of bone, especially cortical bone. The osteogenic factor is most preferably BMP-2 or LMP, or comprises a nucleotide sequence encoding BMP-2 or LMP.
Another embodiment of the present invention provides a method for inducing bone growth in a primate. The method includes a first step of providing an osteogenic sponge composition having a resorbable sponge matrix material and an osteogenic factor that stimulates osteoblasts and osteoclasts incorporated in the sponge matrix material in an amount that causes an increased rate of resorption of the sponge matrix material in the primate. Particulate mineral having an average particle diameter of at least about 0.5 mm is embedded in said resorbable sponge matrix material and present in a weight ratio of at least 4:1 relative to the resorbable sponge matrix material, so as to provide a scaffold for bone ingrowth in the presence of the osteogenic factor. This osteogenic sponge composition is implanted in the primate in a void in which bone growth is desired, with the osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through the void. Particularly preferred methods involve bone ingrowth to attain spinal fusions in humans.
Another preferred embodiment of the invention provides an osteogenic sponge composition effective for the induction of new bone growth in a mammal (especially a primate) that includes
a carrier consisting essentially of a resorbable sponge matrix with particulate mineral embedded in the resorbable sponge matrix, wherein the particulate mineral is present in an amount constituting at least about 95% by weight of the carrier. An osteogenic factor that stimulates osteoblasts and osteoclasts is incorporated in said carrier.
A still further aspect of the invention provides a highly mineralized sponge implant device consisting essentially of a resorbable sponge matrix formed of collagen and having particulate biocompatible mineral embedded within said matrix. In this embodiment, the device is comprised 1% to 3% by weight of the collagen and 97% to 99% by weight of the particulate biocompatible mineral. In another inventive feature, an osteogenic factor can be incorporated in such an implant.
A further embodiment of the invention provides an interbody spinal fusion device that includes a load bearing member sized for insertion between adjacent vertebrae and any one of the aforementioned compositions retained by the load bearing member. Such fusion devices can be used in inventive interbody spinal fusion methods mammals, wherein the devices are appropriately implanted to facilitate spinal fusion.
A particular feature of the present invention relates to the discovery that the inclusion of an osteogenic factor, especially an osteoblast- and osteoclast-stimulating osteogenic factor, in a resorbable sponge composition causes a substantially accelerated resorption of the sponge. This rapid resorption can diminish or eliminate the capacity of the sponge composition to effectively stimulate and support new bone formation in a void filled with the sponge composition. This is particularly the case in primates, including humans, in which the rate of new bone formation is relatively slow. Objects of the present invention are to provide osteogenic sponge compositions effective for the induction of bone growth in mammals, particularly primates, including humans, and related methods and devices. These and other objects and advantages of the present invention will become apparent upon reading the descriptions herein.
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the invention relates.
As described above, the invention relates in certain aspects to osteogenic sponge compositions effective for the induction of new bone growth in mammals and methods for inducing bone growth in mammals. The present invention features osteogenic sponge compositions effective for use in primates, wherein the compositions exhibit high osteoinductive potential and provide a lasting mineral scaffold to support bone ingrowth. Such preferred compositions include a porous, resorbable sponge carrier, such as collagen in sponge form, and an osteogenic factor that stimulates the action of both osteoblasts (which biologically facilitate the formation of bone) and osteoclasts (which biologically facilitate the resorption of bone). In accordance with the present invention, it has been found that the incorporation of an effective inductive amount of an osteogenic factor, such as a bone morphogenetic protein (BMP), stimulates osteoclasts to such a level that a porous resorbable carrier is quickly resorbed and, in the absence of a high mineral component in the composition, causes the performance of the composition to suffer in some cases to the extent that the observation of substantial bone ingrowth is sporadic. Although such non-mineralized sponge compositions may be highly effective for repair of bone defects in lower animals, such as mice, that have a faster bone growth rate, they are less effective in large animals such as primates, including humans.
Accordingly, a feature of the present invention is the provision of an osteogenic composition in the form of a sponge that includes a substantial amount of a relatively slowly-resorbed mineral component that remains at the implant site after the carrier has been rapidly resorbed, in order to provide a scaffold for new bone formation that is not prematurely resorbed due to the osteoclastic potentiation by the bone morphogenic protein in the composition. The present invention also provides methods for using such osteogenic compositions in treatment of bone trauma, disease and defects, for artificial arthrodeses and for other treatment where new bone formation is desired, especially in primates, including humans.
The sponge matrix material is preferably collagenous. A wide variety of collagen materials are suitable for the sponge matrix. Naturally occurring collagens may be subclassified into several different types depending on their amino acid sequence, carbohydrate content and presence or absence of disulfide cross-links. Types I and III collagen are two of the most common subtypes of collagen. Type I collagen is present in skin, tendon and bone whereas Type III collagen is found primarily in skin. The collagen in the composition may be obtained from skin, bone, tendon, or cartilage and purified by methods known in the art. Alternatively, the collagen may be purchased commercially. The collagen in the composition is preferably Type I bovine collagen.
The collagen carrier can further be atelopeptide collagen and/or telopeptide collagen. Moreover, both non-fibrillar and fibrillar collagen may be used. Non-fibrillar collagen is collagen that has been solubilized and has not been reconstituted into its native fibrillar form.
The sponge carrier may also be formed of other natural or synthetic polymeric materials, in addition to or as an alternative to collagen. For example, the sponge carrier may be formed of gelatin (e.g. foamed gelatin), in addition collagen or as an alternative to collagen. Other natural and synthetic polymers are also known for the formation of biocompatible sponge materials, and can be used herein.
As indicated above, preferred compositions of the invention also include an osteoinductive factor, such as an osteoinductive protein or a nucleotide sequence encoding an osteoinductive protein operably associated with a promoter (e.g. provided in a vector such as a viral vector) which drives expression of the gene in the animal recipient to produce an effective amount of the protein. The osteogenic factor utilized in the present invention can be one that stimulates production or activity of osteoblasts and osteoclasts. The factor is preferably a bone morphogenetic protein (BMP) or a LIM mineralization protein (LMP), or comprises a nucleotide sequence encoding a BMP or LMP. Recombinant human BMPs are preferred, and may be commercially obtained or prepared as described and known in the art, e.g. in U.S. Pat. Nos. 5,187,076 to Wozney et al.; 5,366,875 to Wozney et al.; 4,877,864 to Wang et al.; 5,108,932 to Wang et al.; 5,116,738 to Wang et al.; 5,013,649 to Wang et al.; 5,106,748 to Wozney et al; and PCT Patent Nos. WO93/00432 to Wozney et al.; WO94/2693 to Celeste et al.; and WO94/26892 to Celeste et al. Further, the osteoinductive factor may be isolated from bone. Methods for isolating BMP from bone are described in U.S. Pat. No. 4,294,753 to Urist and Urist et al., PNAS 371, 1984. Recombinant human BMP-2 (rhBMP-2), recombinant human BMP-4 (rhBMP-4), recombinant human BMP-7 (rhBMP-7) or heterodimers thereof are most preferred. The osteoinductive factor may also be LIM mineralization protein (LMP) or a suitable vector incorporating a gene encoding the same operably associated with a promoter, as described in WO99/06563 (see also genbank accession No. AF095585). When such vectors are employed as osteogenic factors in accordance with the invention, they are preferably delivered in conjunction with cells, for example autologous cells from the recipient of the implant. Most preferably the vector is delivered in conjunction with autologous white blood cells derived from bone marrow or peripheral blood of the recipient. These cells may be applied to the sponge composition along with the osteogenic factor prior to implantation.
The particulate mineral component includes a natural or synthetic mineral that is effective in providing a scaffold for bone ingrowth as the resorbable carrier is resorbed. The mineral may be, for example, bone, especially cortical bone, or a synthetic bioceramic such as a biocompatible calcium phosphate ceramic. Illustrative ceramics include tricalcium phosphate, hydroxyapatite, and biphasic calcium phosphate. These mineral components may be purchased commercially or obtained or synthesized by methods known in the art.
Biphasic calcium phosphate is a particularly preferred synthetic ceramic for use in the invention. Desirably, such biphasic calcium phosphate with have a tricalcium phosphate:hydroxyapatite weight ratio of about 50:50 to about 95:5, more preferably about 70:30 to about 95:5, even more preferably about 80:20 to about 90:10, and most preferably about 85:15.
In general, the amount of mineral in the osteogenic sponge composition must be sufficient to provide a scaffold that will remain in the patient for a period of time sufficient for the formation of osteoid in the void for which bone growth is desired. Typically, this period of time will be about 6 to about 8 weeks. The minimum level of mineral that must be present in the composition is also dependent on the activity of the BMP in the composition; the higher the activity of the BMP, the greater the content of the mineral matrix required to counter the osteoclastic potentiation of the BMP. The rate of resorption of the resorbable carrier also increases as the BMP concentration increases.
In preferred aspects of the invention, the particulate mineral:resorbable sponge matrix weight ratio will be at least about 4:1, more preferably at least about 10:1. In particularly preferred sponge implants, the particulate mineral will constitute at least 95% by weight of the sponge implant. For example, highly effective sponge carrier devices are provided wherein they comprise about 97% to about 99% by weight particulate mineral and about 1% to about 3% of the collagen or other sponge-forming matrix material. Moreover, it is preferred that the mineral component have an average particle size of at least about 0.5 mm, more preferably about 0.5 mm to about 5 mm, and most preferably about 1 mm to about 3 mm.
To make the sponge implant, a collagen slurry may be formed as known and preferably is chilled to increase its viscosity to help suspend the porous particulate mineral component. The porous particulate mineral is dispersed into the collagen slurry and gently mixed. After the porous particulate mineral component is uniformly dispersed in the slurry, the slurry is poured into sterile trays or other forms and freeze dried. The sheets of composite sponge are then removed from the freeze drier and exposed to a gluteraldehyde cross-linking agent. The composite sponge formed is generally three-dimensionally stable and can be sterilized and packaged in accordance with known procedures.
The dimensions of the sponge produced may vary depending on the application. Dimensions of a typical sponge are, for example, about 10 cm (length)×7.5 cm (width)×0.35 cm (height).
As one example, BMP or other osteogenic factors may be included in the formed sponge by combining the BMP with a liquid carrier as known in the art and infusing the liquid into the sponge.
As further enhancements of the compositions of the present invention, those skilled in the art will readily appreciate that other osteogenic enhancing factors may be incorporated into the composition. Such additional factors include host compatible osteogenic progenitor cells, autographic bone marrow, allographic bone marrow, transforming growth factor-β, fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, microglobulin-β, antibiotics and steroids.
In yet another aspect of the invention, methods for inducing bone growth in mammals are provided. The methods include providing the above-described osteogenic sponge composition and implanting the composition at a site at which bone growth is desired, e.g., to treat a disease, defect or location of trauma, and/or to promote artificial arthrodesis. The hydrated sponge composition may be rolled up prior to packing the sponge into the implantation site.
Once in place, the osteogenic sponge composition will effectively induce and support ingrowth of bone into the desired area even in a primate such as a human that exhibits a relatively slow rate of bone formation compared to smaller mammals, such as rodents or rabbits. Although the collagen carrier is resorbed relatively quickly, the substantial mineral component remains as a scaffolding to support new bone growth in and through the desired area.
The above osteogenic sponge compositions of the present invention are especially advantageous when used in bones or bone portions that exhibit only low to moderate vascularization. Such low to moderate vascularized regions exhibit low rates of bone formation so rapid resorption of a carrier poses a problem. Examples of low to moderate vascularized sites include, for example, transverse processes or other posterior elements of the spine.
An especially preferred use of the sponge compositions of the present invention is as an implant to promote arthrodesis between vertebrae in spinal fusions in humans or other primates, including interbody, posterior and/or posterolateral fusion techniques. Although the rate of bone formation in the primate spine is relatively slow overall and thus will benefit generally from the present invention, the elements to be fused in posterior and posterolateral fusions exhibit particularly low levels of vascularization and thus fusions of these elements are expected to benefit markedly from the invention.
Moreover, the osteogenic sponge compositions can be incorporated with a load-bearing member used in a spinal fusion, including hollow spinal cages, dowels or other devices known in the art having a pocket, chamber or other mechanism for retaining the osteogenic sponge composition. The load-bearing member desirably will have a compressive strength of at least about 10,000 N. Suitable such load bearing members are described, for example in U.S. Pat. Nos. 5,522,899, 5,785,710, 5,776,199 and 5,814,084, each of which is hereby incorporated by reference in its entirety.
Reference will now be made to specific examples using the processes described above. It is to be understood that the examples are illustrative and not limiting of the invention.
12 grams of deproteinized cortical bone chips, 1-3 mm in size, were added to 12 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm×10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.
12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 12 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm×10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.
12 grams of deproteinized cortical bone chips, 1-3 mm in size, were added to 24 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm×10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.
12 grams of biphasic calcium phosphate particles, 1 mm in diameter, were added to 24 grams of collagen slurry (0.192 grams of collagen). This composite slurry was poured into a 7.5 cm×10.0 cm mold, freeze dried, double sterile packaged, and sterilized by ETO gas sterilization.
The present study was performed to determine the effect of the osteogenic sponge compositions of the present invention on spinal fusion.
The experimental group included two adult rhesus monkeys (Macaca mulatta). The monkeys were anesthetized with 3-5 mg/kg telazol intramuscularly (i.m.). The anesthesia was maintained with 1.5-2.0% isoflurane. After anesthesia was achieved, animals were shaved, prepared with betadine and sterily draped. The surgical site was infiltrated with 10-15 ml of 0.25% marcaine to aid with immediate postoperative analgesia. A midlineposterior skin incision was made over the lumbar spine. The paraspinal muscles were reflected using elevators, exposing the lamina and the transverse processes of the L4 and L5 vertebral bodies. The transverse processes of the two vertebrae to be fused were decorticated with an electric burr.
Composite sponges, having dimension of 3.5 cm×1.4 cm×0.35 cm, were prepared using techniques as described in Examples 1 and 2. The sponges included, on a weight basis, 97% biphasic calcium phosphate (15% hydroxyapatite and 85% tricalcium phosphate, 1 mm particle size) and 3% collagen. Recombinant human BMP-2 (rhBMP-2) was prepared at a concentration of 3.0 mg/ml in a buffered solution. Each sponge was infused with 1.5 ml of the rhBMP-2 solution.
The sponges were placed in the paraspinal bed directly on top of and bridging the two adjacent transverse processes. The sponges were placed bilaterally, with two sponges (one on top of the other) on each side of the spine, resulting in a total dose of 9 mg rhBMP-2 per implant site. The animals were allowed to recover and move around ad libitum without restrictions during the study period.
The spines were manually assessed for fusion upon sacrifice (2, 4 and 6 months) and determined to be fused based upon the absence of motion during attempted bending, and presence of histological bridging bone.
The fusions were also evaluated by CT scan at 2, 4 and 6 months after implantation. FIGS. 1 and 2 show the CT scans for each subject studied. FIGS. 1 and 2 demonstrate the sequence of events that occur within the composite sponge carrier loaded with rhBMP-2. On the far left of the figures are three CT sections equally spaced throughout the fusion mass at 2 months post-operative, showing that resorption of the composite sponge is just about complete due to the lack of radiopacity of the ceramic granules. The three middle CT sections show these same three CT sections at four months with increased bone deposition where the carrier once resided. The composite sponge has maintained the space within the soft tissue site for a sufficient enough period of time for the desired volume of new bone deposition to occur. Finally, the far right three CT scans show even further bone deposition, remodeling and maturation with the formation of outer cortices around the periphery of the fusion masses by six months.
Claims (20)
1. A method for inducing bone growth in a primate, comprising:
(a) providing an osteogenic sponge composition comprising:
a resorbable sponge matrix material comprising collagen;
an osteogenic factor that stimulates osteoblasts and osteoclasts, said osteogenic factor incorporated in said sponge matrix material in an amount that causes an increased rate of resorption of said sponge matrix material in the primate; and
a particulate mineral having an average particle diameter of at least about 0.5 mm embedded in said resorbable sponge matrix material, the sponge matrix being three-dimensionally stable but flexible and comprising 95% to 99% by weight of said particulate mineral so as to provide a scaffold for bone ingrowth in the presence of said ostegenic factor; and
(b) implanting said osteogenic sponge composition in an area in which bone growth is desired in the primate, said osteogenic sponge composition providing a scaffold for a duration sufficient for osteoid ingrowth through an area in which said osteogenic sponge composition is implanted.
2. The method of claim 1 , wherein said particulate mineral is present in an amount of 97% to 99% by weight of the osteoinductive sponge composition.
3. The method of claim 2 , wherein said osteogenic factor comprises a bone morphogenetic protein, a LIM mineralization protein, or a nucleotide sequence encoding a bone morphogenetic protein or LIM mineralization protein.
4. The method of claim 1 , wherein said resorbable sponge matrix material includes 1% to 3% by weight collagen.
5. The method of claim 3 , wherein said resorbable sponge matrix material includes 1% to 3% by weight collagen.
6. The method of claim 1 , wherein said particulate mineral is selected from the group consisting bone, a synthetic biocompatible calcium phosphate ceramic, or a mixture thereof.
7. The method of claim 6 , wherein said particulate mineral comprises biphasic calcium phosphate that is porous.
8. The method of claim 7 , wherein said biphasic calcium phosphate has a porosity of at least about 50%.
9. The method of claim 1 , wherein said particulate mineral includes bone particles.
10. The method of claim 9 , wherein said bone particles are cortical bone particles.
11. The method of claim 1 , wherein said osteoinductive sponge composition comprises 95% by weight of said particulate mineral.
12. The method of claim 1 , wherein said particulate mineral has an average particle size of about 0.5 mm to about 5.0 mm.
13. The method of claim 1 , wherein said particulate mineral is porous and has an average particle size of about 1 to about 2 mm.
14. The method of claim 1 , wherein said osteogenic factor is a bone morphogenetic protein.
15. The method of claim 14 , wherein said bone morphogenetic protein is a recombinant human protein.
16. The method of claim 14 , wherein said bone morphogenetic protein is BMP-2 or BMP-7.
17. The method of claim 1 , wherein the primate is a human.
18. The method of claim 1 , wherein the area is in the spine of said primate.
19. The method of claim 18 , wherein the bone growth is induced to attain a spinal fusion.
20. The method of claim 19 , wherein the spinal fusion is an interbody spinal fusion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/369,929 US8399010B2 (en) | 1999-02-04 | 2012-02-09 | Highly-mineralized osteogenic sponge compositions and uses thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11861599P | 1999-02-04 | 1999-02-04 | |
PCT/US2000/003043 WO2000045871A1 (en) | 1999-02-04 | 2000-02-04 | Highly-mineralized osteogenic sponge compositions, and uses thereof |
US09/923,116 US7563455B2 (en) | 1999-02-04 | 2001-08-06 | Highly-mineralized osteogenic sponge compositions, and uses thereof |
US12/355,569 US8147862B2 (en) | 1999-02-04 | 2009-01-16 | Highly mineralized osteogenic sponge compositions and uses thereof |
US13/369,929 US8399010B2 (en) | 1999-02-04 | 2012-02-09 | Highly-mineralized osteogenic sponge compositions and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/355,569 Continuation US8147862B2 (en) | 1999-02-04 | 2009-01-16 | Highly mineralized osteogenic sponge compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120141557A1 US20120141557A1 (en) | 2012-06-07 |
US8399010B2 true US8399010B2 (en) | 2013-03-19 |
Family
ID=22379695
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/923,116 Expired - Fee Related US7563455B2 (en) | 1999-02-04 | 2001-08-06 | Highly-mineralized osteogenic sponge compositions, and uses thereof |
US12/355,569 Expired - Fee Related US8147862B2 (en) | 1999-02-04 | 2009-01-16 | Highly mineralized osteogenic sponge compositions and uses thereof |
US13/369,929 Expired - Fee Related US8399010B2 (en) | 1999-02-04 | 2012-02-09 | Highly-mineralized osteogenic sponge compositions and uses thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/923,116 Expired - Fee Related US7563455B2 (en) | 1999-02-04 | 2001-08-06 | Highly-mineralized osteogenic sponge compositions, and uses thereof |
US12/355,569 Expired - Fee Related US8147862B2 (en) | 1999-02-04 | 2009-01-16 | Highly mineralized osteogenic sponge compositions and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (3) | US7563455B2 (en) |
EP (1) | EP1150726B1 (en) |
JP (1) | JP2002536077A (en) |
AT (1) | ATE253385T1 (en) |
AU (1) | AU772682B2 (en) |
CA (1) | CA2362049A1 (en) |
DE (1) | DE60006356T2 (en) |
ES (1) | ES2209820T3 (en) |
WO (1) | WO2000045871A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289452B2 (en) | 2013-03-07 | 2016-03-22 | Allosource | Consistent calcium content bone allograft systems and methods |
US9364328B2 (en) | 2011-11-17 | 2016-06-14 | Allosource | Multi-piece machine graft systems and methods |
US9603710B2 (en) | 2013-03-15 | 2017-03-28 | Allosource | Methods of manufacturing perforated osteochondral allograft compositions |
US9730796B2 (en) | 2014-05-16 | 2017-08-15 | Allosource | Composite bone constructs and methods |
US9744266B2 (en) | 2011-12-19 | 2017-08-29 | Allosource | Flowable matrix compositions and methods |
US9808558B2 (en) | 2008-11-20 | 2017-11-07 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
US10130678B2 (en) | 2014-12-29 | 2018-11-20 | Bioventus, LLC. | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
US10335281B2 (en) | 2013-02-22 | 2019-07-02 | Allosource | Cartilage mosaic compositions and methods |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US11229725B2 (en) | 2013-03-15 | 2022-01-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
US11452796B2 (en) | 2017-06-30 | 2022-09-27 | Allosource | Cellular bone grafts, and methods of manufacture and use |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
ES2209820T3 (en) * | 1999-02-04 | 2004-07-01 | Sdgi Holdings, Inc. | HIGHLY MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS, AND USES OF THE SAME. |
AU770196B2 (en) * | 1999-02-04 | 2004-02-12 | Warsaw Orthopedic, Inc. | Osteogenic paste compositions and uses thereof |
US7435260B2 (en) * | 1999-08-13 | 2008-10-14 | Ferree Bret A | Use of morphogenetic proteins to treat human disc disease |
EP2085055B1 (en) * | 2000-10-24 | 2012-06-06 | Warsaw Orthopedic, Inc. | Spinal fusion devices |
US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
BR0214275A (en) | 2001-11-19 | 2004-09-21 | Scil Technology Gmbh | Device having osteoconductive and osteoinductive properties |
JP2003169845A (en) * | 2001-12-07 | 2003-06-17 | Japan Science & Technology Corp | Sponge-like porous apatite-collagen composite, sponge-like superporous apatite-collagen composite and method of manufacturing the same |
TW200400062A (en) | 2002-04-03 | 2004-01-01 | Mathys Medizinaltechnik Ag | Kneadable, pliable bone replacement material |
US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
ES2260685T3 (en) | 2002-09-10 | 2006-11-01 | Scil Technology Gmbh | METALLIC IMPLANT COVERED, TO A REDUCED OXYGEN CONCENTRATION, WITH OSTEOINDUCTING PROTEIN. |
WO2004041319A1 (en) * | 2002-11-07 | 2004-05-21 | Pentax Corporation | Therapeutic device for osteogenesis |
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US20070010892A1 (en) * | 2003-08-27 | 2007-01-11 | Makoto Ogiso | Structural body constituted of biocompatible material impregnated with fine bone dust and process for producing the same |
US7666230B2 (en) | 2003-12-08 | 2010-02-23 | Depuy Products, Inc. | Implant device for cartilage regeneration in load bearing articulation regions |
US7189263B2 (en) | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
US20050192675A1 (en) * | 2004-03-01 | 2005-09-01 | Robinson Dane Q. | Device for use in stimulating bone growth |
US9220595B2 (en) | 2004-06-23 | 2015-12-29 | Orthovita, Inc. | Shapeable bone graft substitute and instruments for delivery thereof |
JP2008513100A (en) * | 2004-09-14 | 2008-05-01 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Porous biomaterial-filler composite and process for producing the same |
US7722895B1 (en) * | 2004-09-20 | 2010-05-25 | Warsaw Orthopedic, Inc. | Osteogenic implants with combined implant materials, and materials and methods for same |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20090319045A1 (en) | 2004-10-12 | 2009-12-24 | Truncale Katherine G | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US20060083769A1 (en) * | 2004-10-14 | 2006-04-20 | Mukesh Kumar | Method and apparatus for preparing bone |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7670384B2 (en) * | 2004-10-14 | 2010-03-02 | Biomet Manufacturing Corp. | Bone graft composition comprising a bone material and a carrier comprising denatured demineralized bone |
DE102005016443A1 (en) * | 2004-11-23 | 2006-05-24 | Ossacur Ag | Bioabsorbable and mineralized material, useful for filling of bone defects, comprises a collagen matrix from aggregated collagen chains, where only the surface of the aggregated collagen chain is mineralized |
WO2006089359A1 (en) * | 2005-02-25 | 2006-08-31 | Eugene Sherry | Replacement bone tissue |
WO2006113586A2 (en) | 2005-04-15 | 2006-10-26 | Musculoskeletal Transplant Foundation | Vertebral disc repair |
US8506646B2 (en) * | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
US7857853B2 (en) * | 2005-04-29 | 2010-12-28 | Sdgi Holdings, Inc | Synthetic loadbearing collagen-mineral composites useful for spinal implants, and methods of manufacture |
US8092548B2 (en) * | 2005-06-22 | 2012-01-10 | Warsaw Orthopedic, Inc. | Osteograft treatment to promote osteoinduction and osteograft incorporation |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
EP1926459B1 (en) | 2005-09-19 | 2015-01-07 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US20070077267A1 (en) * | 2005-10-03 | 2007-04-05 | Sdgi Holdings, Inc. | Bioactive composite implants |
US9005646B2 (en) | 2005-10-12 | 2015-04-14 | Lifenet Health | Compositions for repair of defects in tissues, and methods of making the same |
US9132208B2 (en) * | 2008-08-07 | 2015-09-15 | Lifenet Health | Composition for a tissue repair implant and methods of making the same |
EP1951327A2 (en) | 2005-11-17 | 2008-08-06 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
US7939092B2 (en) * | 2006-02-01 | 2011-05-10 | Warsaw Orthopedic, Inc. | Cohesive osteogenic putty and materials therefor |
US7824703B2 (en) | 2006-02-01 | 2010-11-02 | Warsaw Orthopedics, Inc. | Medical implants with reservoir(s), and materials preparable from same |
WO2007092622A2 (en) * | 2006-02-09 | 2007-08-16 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
US7833270B2 (en) * | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
JP5484047B2 (en) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | PDGF-biomatrix composition and method for treating rotator cuff injury |
US9161967B2 (en) * | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
WO2008013763A2 (en) | 2006-07-25 | 2008-01-31 | Musculoskeletal Transplant Foundation | Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation |
US8524265B2 (en) * | 2006-08-17 | 2013-09-03 | Warsaw Orthopedic, Inc. | Medical implant sheets useful for tissue regeneration |
EP2086598B1 (en) | 2006-11-03 | 2015-05-27 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
US20080147197A1 (en) * | 2006-12-14 | 2008-06-19 | Mckay William F | Biodegradable osteogenic porous biomedical implant with impermeable membrane |
US8048857B2 (en) * | 2006-12-19 | 2011-11-01 | Warsaw Orthopedic, Inc. | Flowable carrier compositions and methods of use |
US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
US20080195476A1 (en) * | 2007-02-09 | 2008-08-14 | Marchese Michael A | Abandonment remarketing system |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
WO2008128342A1 (en) * | 2007-04-18 | 2008-10-30 | Mcgill University | Composition for enhancing bone formation |
EP2014256A1 (en) | 2007-07-12 | 2009-01-14 | Straumann Holding AG | Composite bone repair material |
WO2009038783A1 (en) | 2007-09-19 | 2009-03-26 | Surmodics, Inc. | Biocompatible foams, systems, and methods |
US20090110637A1 (en) * | 2007-10-26 | 2009-04-30 | Warsaw Orthopedic, Inc. | LMP and Regulation of Tissue Growth |
US9056150B2 (en) * | 2007-12-04 | 2015-06-16 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
CN102014977B (en) * | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | For compositions and the method for Distraction Osteogenesis |
US8840913B2 (en) * | 2008-03-27 | 2014-09-23 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
WO2009128076A2 (en) | 2008-04-18 | 2009-10-22 | Collplant Ltd. | Methods of generating and using procollagen |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
US8039433B2 (en) * | 2008-08-19 | 2011-10-18 | Warsaw Orthopedic, Inc. | Osteogenic compositions containing a coloring agent |
BRPI0918611B8 (en) | 2008-09-09 | 2021-06-22 | Biomimetic Therapeutics Inc | composition comprising a biocompatible matrix and a platelet-derived growth factor and kit |
WO2010102266A1 (en) * | 2009-03-05 | 2010-09-10 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
US20110060419A1 (en) * | 2009-03-27 | 2011-03-10 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
WO2011063152A1 (en) * | 2009-11-18 | 2011-05-26 | Affinergy, Inc. | Methods and compositions for soft tissue repair |
US8758791B2 (en) | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
US8475824B2 (en) | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
CN107080834A (en) | 2010-02-22 | 2017-08-22 | 生物模拟治疗有限责任公司 | Platelet-derived growth factor compositions and method for treating tendon disease |
US8501690B2 (en) | 2010-04-30 | 2013-08-06 | John G. Stark | Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue |
ES2911190T3 (en) | 2010-05-11 | 2022-05-18 | Howmedica Osteonics Corp | Organophosphorus compounds, multivalent metals and polymeric adhesive interpenetrating network compositions and methods |
KR101800596B1 (en) | 2010-08-20 | 2017-11-22 | 와이어쓰 엘엘씨 | Designer osteogenic proteins |
US8613938B2 (en) | 2010-11-15 | 2013-12-24 | Zimmer Orthobiologics, Inc. | Bone void fillers |
US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
US9358122B2 (en) | 2011-01-07 | 2016-06-07 | K2M, Inc. | Interbody spacer |
US9717779B2 (en) | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
EP2678051B1 (en) * | 2011-02-25 | 2016-11-09 | DePuy Synthes Products, LLC | Osteogenic promoting implants and methods of inducing bone growth |
US8765189B2 (en) | 2011-05-13 | 2014-07-01 | Howmedica Osteonic Corp. | Organophosphorous and multivalent metal compound compositions and methods |
EP2529764A1 (en) | 2011-05-31 | 2012-12-05 | Curasan AG | Biodegradable composite material |
WO2012177759A1 (en) | 2011-06-20 | 2012-12-27 | Rdc Holdings, Llc | System and method for repairing joints |
US8998925B2 (en) | 2011-06-20 | 2015-04-07 | Rdc Holdings, Llc | Fixation system for orthopedic devices |
US9642933B2 (en) | 2012-01-30 | 2017-05-09 | Board Of Regents, The University Of Texas System | Compositions comprising bioadhesives and methods of making the same |
WO2013123509A1 (en) * | 2012-02-17 | 2013-08-22 | Bacterin International, Inc. | Adjustable bioactive agent dispersion within a polymeric coating |
US8697107B2 (en) | 2012-04-27 | 2014-04-15 | Warsaw Orthopedic, Inc. | Flowable implant with crosslinkable surface membrane |
US10207027B2 (en) | 2012-06-11 | 2019-02-19 | Globus Medical, Inc. | Bioactive bone graft substitutes |
US9585764B2 (en) * | 2012-07-26 | 2017-03-07 | Warsaw Orthopedic, Inc. | Bone implant device |
US9492477B2 (en) * | 2013-01-04 | 2016-11-15 | Board Of Regents, The University Of Texas System | Compositions comprising citrate and applications thereof |
BR112015016264A2 (en) * | 2013-03-14 | 2017-07-11 | Genzyme Corp | thermosensitive bone growth compositions |
US9539286B2 (en) | 2013-10-18 | 2017-01-10 | Globus Medical, Inc. | Bone grafts including osteogenic stem cells, and methods relating to the same |
US9486483B2 (en) | 2013-10-18 | 2016-11-08 | Globus Medical, Inc. | Bone grafts including osteogenic stem cells, and methods relating to the same |
US9579421B2 (en) | 2014-02-07 | 2017-02-28 | Globus Medical Inc. | Bone grafts and methods of making and using bone grafts |
US9463264B2 (en) | 2014-02-11 | 2016-10-11 | Globus Medical, Inc. | Bone grafts and methods of making and using bone grafts |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US10016529B2 (en) | 2015-06-10 | 2018-07-10 | Globus Medical, Inc. | Biomaterial compositions, implants, and methods of making the same |
US11426489B2 (en) | 2015-06-10 | 2022-08-30 | Globus Medical, Inc. | Biomaterial compositions, implants, and methods of making the same |
WO2017100339A1 (en) * | 2015-12-07 | 2017-06-15 | Nuvasive, Inc. | Immunomodulation with implantation of cellular allograft bone into a non-bony site |
US20170319750A1 (en) * | 2016-05-09 | 2017-11-09 | Bioventus, Llc | Composite matrices designed for enhanced bone repair |
EP3388092A1 (en) | 2017-04-13 | 2018-10-17 | Septodont ou Septodont SAS ou Specialites Septodont | Connective tissues, such as bone, dentin or pulp, regenerative material comprising calcium silicate |
ES2906850T3 (en) | 2017-04-13 | 2022-04-20 | Septodont Ou Septodont Sas Ou Specialites Septodont | Connective tissues, such as bone, dentin or pulp, regenerative material comprising calcium silicate |
US11896736B2 (en) | 2020-07-13 | 2024-02-13 | Globus Medical, Inc | Biomaterial implants and methods of making the same |
US11883302B2 (en) | 2021-11-22 | 2024-01-30 | Warsaw Orthopedic, Inc. | Spinal implant having a compressible insert |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
US4516276A (en) | 1979-12-18 | 1985-05-14 | Oscobal Ag | Bone substitute and a method of production thereof |
US4743229A (en) | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
US4776890A (en) | 1985-12-18 | 1988-10-11 | Collagen Corporation | Preparation of collagen hydroxyapatite matrix for bone repair |
US4780450A (en) | 1985-12-20 | 1988-10-25 | The University Of Maryland At Baltimore | Physically stable composition and method of use thereof for osseous repair |
US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
EP0309241A2 (en) | 1987-09-25 | 1989-03-29 | Collagen Corporation | Inductive collagen-based bone repair preparations |
WO1989004646A1 (en) | 1987-11-13 | 1989-06-01 | Jefferies Steven R | Bone repair material and delayed drug delivery |
US4861733A (en) | 1987-02-13 | 1989-08-29 | Interpore International | Calcium phosphate bone substitute materials |
US4865602A (en) | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
US4992226A (en) | 1985-03-28 | 1991-02-12 | Collagen Corporation | Method of making molds with xenogeneic collagen/mineral preparations for bone repair |
US5001169A (en) | 1984-10-24 | 1991-03-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
EP0530804A1 (en) | 1991-09-06 | 1993-03-10 | Shaw, Robert Francis | Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5231169A (en) | 1990-10-17 | 1993-07-27 | Norian Corporation | Mineralized collagen |
US5246457A (en) | 1985-03-28 | 1993-09-21 | Collagen Corporation | Xenogeneic collagen/mineral preparations in bone repair |
US5273964A (en) | 1985-03-20 | 1993-12-28 | Lemons J E | Inorganic and organic composition for treatment of bone lesions |
US5573771A (en) | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
EP0747067A2 (en) | 1995-06-07 | 1996-12-11 | Collagen Corporation | Moldable collagen compositions for hard tissue repair and augmentation |
WO1996039203A1 (en) | 1995-06-06 | 1996-12-12 | Gensci Regeneration Laboratories, Inc. | Modified osteogenic materials |
US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
WO1997031661A1 (en) | 1996-02-29 | 1997-09-04 | Lindholm T Sam | An osteogenic device and a method for preparing the device |
WO1997040137A1 (en) | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
US5702449A (en) | 1995-06-07 | 1997-12-30 | Danek Medical, Inc. | Reinforced porous spinal implants |
US5741261A (en) * | 1996-06-25 | 1998-04-21 | Sdgi Holdings, Inc. | Minimally invasive spinal surgical methods and instruments |
WO1998017330A1 (en) | 1996-10-24 | 1998-04-30 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions containing osteoinductive factors |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
US5785710A (en) | 1988-06-13 | 1998-07-28 | Sofamor Danek Group, Inc. | Interbody spinal fusion implants |
US5874109A (en) | 1994-07-27 | 1999-02-23 | The Trustees Of The University Of Pennsylvania | Incorporation of biological molecules into bioactive glasses |
US5972368A (en) | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
US7563455B2 (en) * | 1999-02-04 | 2009-07-21 | Warsaw Orthopedic, Inc. | Highly-mineralized osteogenic sponge compositions, and uses thereof |
-
2000
- 2000-02-04 ES ES00905989T patent/ES2209820T3/en not_active Expired - Lifetime
- 2000-02-04 EP EP00905989A patent/EP1150726B1/en not_active Expired - Lifetime
- 2000-02-04 AU AU27568/00A patent/AU772682B2/en not_active Ceased
- 2000-02-04 AT AT00905989T patent/ATE253385T1/en not_active IP Right Cessation
- 2000-02-04 DE DE60006356T patent/DE60006356T2/en not_active Expired - Fee Related
- 2000-02-04 WO PCT/US2000/003043 patent/WO2000045871A1/en active IP Right Grant
- 2000-02-04 JP JP2000596990A patent/JP2002536077A/en active Pending
- 2000-02-04 CA CA002362049A patent/CA2362049A1/en not_active Abandoned
-
2001
- 2001-08-06 US US09/923,116 patent/US7563455B2/en not_active Expired - Fee Related
-
2009
- 2009-01-16 US US12/355,569 patent/US8147862B2/en not_active Expired - Fee Related
-
2012
- 2012-02-09 US US13/369,929 patent/US8399010B2/en not_active Expired - Fee Related
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4516276A (en) | 1979-12-18 | 1985-05-14 | Oscobal Ag | Bone substitute and a method of production thereof |
US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
US5001169A (en) | 1984-10-24 | 1991-03-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
US4888366A (en) | 1984-10-24 | 1989-12-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
US5273964A (en) | 1985-03-20 | 1993-12-28 | Lemons J E | Inorganic and organic composition for treatment of bone lesions |
US5425770A (en) | 1985-03-28 | 1995-06-20 | Collagen Corporation | Calcium phosphate/atelopeptide collagen compositions for bone repair |
US5246457A (en) | 1985-03-28 | 1993-09-21 | Collagen Corporation | Xenogeneic collagen/mineral preparations in bone repair |
US4992226A (en) | 1985-03-28 | 1991-02-12 | Collagen Corporation | Method of making molds with xenogeneic collagen/mineral preparations for bone repair |
US4776890A (en) | 1985-12-18 | 1988-10-11 | Collagen Corporation | Preparation of collagen hydroxyapatite matrix for bone repair |
US4780450A (en) | 1985-12-20 | 1988-10-25 | The University Of Maryland At Baltimore | Physically stable composition and method of use thereof for osseous repair |
US4743229A (en) | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
US4865602A (en) | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
US5123925A (en) | 1986-11-06 | 1992-06-23 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
US5035715A (en) | 1986-11-06 | 1991-07-30 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
US4861733A (en) | 1987-02-13 | 1989-08-29 | Interpore International | Calcium phosphate bone substitute materials |
EP0309241A2 (en) | 1987-09-25 | 1989-03-29 | Collagen Corporation | Inductive collagen-based bone repair preparations |
WO1989004646A1 (en) | 1987-11-13 | 1989-06-01 | Jefferies Steven R | Bone repair material and delayed drug delivery |
US5785710A (en) | 1988-06-13 | 1998-07-28 | Sofamor Danek Group, Inc. | Interbody spinal fusion implants |
US5573771A (en) | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
US5231169A (en) | 1990-10-17 | 1993-07-27 | Norian Corporation | Mineralized collagen |
EP0530804A1 (en) | 1991-09-06 | 1993-03-10 | Shaw, Robert Francis | Kits and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
US5874109A (en) | 1994-07-27 | 1999-02-23 | The Trustees Of The University Of Pennsylvania | Incorporation of biological molecules into bioactive glasses |
WO1996039203A1 (en) | 1995-06-06 | 1996-12-12 | Gensci Regeneration Laboratories, Inc. | Modified osteogenic materials |
US5702449A (en) | 1995-06-07 | 1997-12-30 | Danek Medical, Inc. | Reinforced porous spinal implants |
EP0747067A2 (en) | 1995-06-07 | 1996-12-11 | Collagen Corporation | Moldable collagen compositions for hard tissue repair and augmentation |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
WO1997031661A1 (en) | 1996-02-29 | 1997-09-04 | Lindholm T Sam | An osteogenic device and a method for preparing the device |
WO1997040137A1 (en) | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
US5741261A (en) * | 1996-06-25 | 1998-04-21 | Sdgi Holdings, Inc. | Minimally invasive spinal surgical methods and instruments |
WO1998017330A1 (en) | 1996-10-24 | 1998-04-30 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions containing osteoinductive factors |
US5972368A (en) | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
US7563455B2 (en) * | 1999-02-04 | 2009-07-21 | Warsaw Orthopedic, Inc. | Highly-mineralized osteogenic sponge compositions, and uses thereof |
US8147862B2 (en) * | 1999-02-04 | 2012-04-03 | Warsaw Orthopedic, Inc. | Highly mineralized osteogenic sponge compositions and uses thereof |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9808558B2 (en) | 2008-11-20 | 2017-11-07 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
US9814803B2 (en) | 2008-11-20 | 2017-11-14 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
US9364328B2 (en) | 2011-11-17 | 2016-06-14 | Allosource | Multi-piece machine graft systems and methods |
US9744266B2 (en) | 2011-12-19 | 2017-08-29 | Allosource | Flowable matrix compositions and methods |
US9801976B2 (en) | 2011-12-19 | 2017-10-31 | Allosource | Flowable matrix compositions and methods |
US9801975B2 (en) | 2011-12-19 | 2017-10-31 | Allosource | Flowable matrix compositions and methods |
US11123193B2 (en) | 2013-02-22 | 2021-09-21 | Allosource | Cartilage mosaic compositions and methods |
US10335281B2 (en) | 2013-02-22 | 2019-07-02 | Allosource | Cartilage mosaic compositions and methods |
US9486556B2 (en) | 2013-03-07 | 2016-11-08 | Allosource | Consistent calcium content bone allograft systems and methods |
US9289452B2 (en) | 2013-03-07 | 2016-03-22 | Allosource | Consistent calcium content bone allograft systems and methods |
US9603710B2 (en) | 2013-03-15 | 2017-03-28 | Allosource | Methods of manufacturing perforated osteochondral allograft compositions |
US11229725B2 (en) | 2013-03-15 | 2022-01-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
US9730796B2 (en) | 2014-05-16 | 2017-08-15 | Allosource | Composite bone constructs and methods |
US10617526B2 (en) | 2014-05-16 | 2020-04-14 | Allosource | Composite bone constructs and methods |
US10130678B2 (en) | 2014-12-29 | 2018-11-20 | Bioventus, LLC. | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
US11452760B2 (en) | 2014-12-29 | 2022-09-27 | Bioventus, Llc | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US11596517B2 (en) | 2015-05-21 | 2023-03-07 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US11452796B2 (en) | 2017-06-30 | 2022-09-27 | Allosource | Cellular bone grafts, and methods of manufacture and use |
Also Published As
Publication number | Publication date |
---|---|
JP2002536077A (en) | 2002-10-29 |
US7563455B2 (en) | 2009-07-21 |
DE60006356T2 (en) | 2004-09-09 |
US20120141557A1 (en) | 2012-06-07 |
ATE253385T1 (en) | 2003-11-15 |
US20090196904A1 (en) | 2009-08-06 |
WO2000045871A1 (en) | 2000-08-10 |
AU2756800A (en) | 2000-08-25 |
ES2209820T3 (en) | 2004-07-01 |
CA2362049A1 (en) | 2000-08-10 |
US8147862B2 (en) | 2012-04-03 |
US20020082694A1 (en) | 2002-06-27 |
DE60006356D1 (en) | 2003-12-11 |
EP1150726A1 (en) | 2001-11-07 |
EP1150726B1 (en) | 2003-11-05 |
AU772682B2 (en) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8399010B2 (en) | Highly-mineralized osteogenic sponge compositions and uses thereof | |
AU770196B2 (en) | Osteogenic paste compositions and uses thereof | |
US8690874B2 (en) | Composition and process for bone growth and repair | |
Alam et al. | Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2 | |
Levine et al. | Bone morphogenetic protein promotes vascularization and osteoinduction in preformed hydroxyapatite in the rabbit | |
EP0616814A1 (en) | Compositions for controlled release of biologically active TGF - beta | |
Breitbart et al. | Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute | |
JP2004262758A (en) | Porous beta-tricalcium phosphate granule and method for producing the same | |
WO2012068135A1 (en) | Bone void fillers | |
US20190117734A1 (en) | System and Method for Multiphasic Release of Growth Factors | |
CA2868992C (en) | System and method for multiphasic release of growth factors | |
US11596712B2 (en) | Autologous bone graft substitute composition | |
US20090061002A1 (en) | Calcium phospate based delivery of growth and differentiation factors to compromised bone | |
Lee | A Pilot Study to Compare the Activity of Different Bone Morphogenetic Protein Bioimplants In Vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20210319 |